The trial confirmed the non-inferiority, but not superiority, of once weekly treatment with 2 mg of the long-acting extended release exenatide (80)
Cannot redeclare control with same name "grid_3_qv_background_color"
Its rich content in monounsaturated fatty acids and PUFAs, as well as antioxidants, polyphenols, and dietary fibre, underlies its multi-targeted benefits, many of which may synergise with pharmacotherapies such as semaglutide to optimise clinical outcomes [112]
Data availability The authors declare that the data supporting the findings of this study are available within the paper and its Supplementary Information files
Consult with your healthcare provider to determine if this is a suitable option
doi:10.1093/oxfordjournals.bmb.a071568 52 Ciftci, H., Verit, A., Savas, M., Yeni, E